GENE THERAPY
Abstract
Background. Gene therapy is a novel approach to treat, cure, or ultimately prevent disease by changing the expression of person’s genes.
Gene therapy is in its inflancy, and current gene therapy is primarily experimental, with most human clinical trials only in the research stages. There were 600 studies initiated from 1990–2001, mostly in USA.
Conclusions. Most of the gene therapy protocols currently tested are for treating various cancers. This is followed by the treatment of cardiovascular diseases, genetic diseases and infectious diseases, the latter mostly to control the HIV infection. About 5 studies devoted to cancer treatment are in the third phase of the trials and may be approved for clinical use in the near future.
Downloads
References
Anon. Guidance for industry. Guidance for human somatic cell therapy and gene therapy. US Dept. of Health and Human Services, FDA, Center for Biologics Evaluation and Research, 1998: 3–4.
Clinical trials in human gene transfer. http://www4.od.nih.gov/oba/rac/ clinicaltrial.htm, Accessed: August 2002.
Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: Current applications and future goals. The Oncologist 1998; 3: 255–63.
Koenig S. Antibody gene therapy with adeno-associated viral vectors. Curr Opp Mol Ther 2001; 3: 433–3.
FDA. http://www.fda.gov/cber/gene.htm, Accessed: September 2001.
Pachori AS, Huentelman MJ, Francis SC, Gelband CH, Katovich MJ, Raizada MK. The future of hypertension therapy: Sense, antisense or nonsense. Hypertension 2001; 37: 357–64.
FDA. http://www.fda.gov/, Accessed: September 2002.
Mountain A. Gene therapy: the first decade. TIBTECH 2000; 18: 119–26.
Blaese RM, Culver KW, Anderson WF. The ADA human gene therapy clinical protocol. Hum Gene Ther 1990; 1: 331–7.
The Jeffrey Modell Foundation. Severe combined immunodeficiency. http:/ /www.jmfworld.org.html/severe_combined_immunodeficien.html, Accessed: May 2002.
OMIM. http://www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmim?202500, Accessed: May 2002.
French-Anderson W. Gene therapy: The best of times, the worst of times. Science 2000; 288: 627–9.
Blaese MR, Culver KW, Miller AD et al. T lymphocyte-directed gene therapy for ADA- SCID: Initial trial results after 4 years. Science 1995; 270: 475–80.
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F et al. Gene therapy of human severe combined immunodeficiency (SCID)-XI disease. Science 2000; 288: 669–9.
J. Gene Medicine. http://www.wiley.co.uk/genetherapy, Accessed: September 2001.
Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999; 401: 517–8.
Smaglik P. Clinical trials at gene therapy institute. Nature 2000; 405: 497–7.
Wadman M. NIH under fire over gene-therapy trials. Nature 2000; 403: 237–7.
Smith AE. Gene therapy – where are we? Lancet 1999; 354: Suppl I: 1–4.
Marshall E. Panel reviews risks of germ line changes. Science 2001; 294: 2268–9.
Zivin JA. Understanding clinical trials. Sci Am 2000; April: 49–55.
Marshall E. Gene Gemisch cures Sicle cell in mice. Science 2001; 294: 2268–8.
Hunt S. Technology evaluation: MetXia-P450, Oxford BioMedica. Curr Opp Mol Ther 2001; 3: 595–8.
Check E. A tragic setback. Nature 2002; 420: 116–8.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
